Previous 10 | Next 10 |
NEW YORK , April 28, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Brian A. Walter , Ph.D., as Vice President of Regul...
Allscripts Healthcare Solutions (NASDAQ: MDRX ) initiated with Outperform rating and $8 (21% upside) price target at RBC. More news on: Allscripts Healthcare Solutions, Inc., Aprea Therapeutics, Inc., Avita Medical Limited, Healthcare stocks news, Stocks on the move, , Read more ...
NEW YORK , March 31, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de Somer , MD, MBA, ScD, MPH, MSc, as Se...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 150 weeks of public selections as part of this ongoing live forward-testing. In...
NEW YORK , March 24, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Judy Caron , Ph.D., as Vice President of Drug Developmen...
NEW YORK , March 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Thomas C. Wessel , M.D., Ph.D., has been appointed the Company's Execut...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 147 weeks of public selections as part of this ongoing live forward-testing. In...
NEW YORK , Feb. 25, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will present a co...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 145 weeks of public selections as part of this ongoing live forward-testing. In...
Today, we will study why Relmada Therapeutics (RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020. Company overview Relmada Therapeutics is a clinical-stage biotechnology company focused on advancing REL-1017 (d-methadone or dextromethadone) as a rapid-acting oral treat...
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry PR Newswire CORAL GABLES, Fla. , June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage b...
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of t...
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 3, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the cent...